Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune adverse events. ICI...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC endocrine disorders 2019-12, Vol.19 (1), p.144-5, Article 144
Hauptverfasser:	Zezza, Marco, Kosinski, Christophe, Mekoguem, Carine, Marino, Laura, Chtioui, Haithem, Pitteloud, Nelly, Lamine, Faiza
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Aged, 80 and over Antibodies Antigens Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Apoptosis Autoimmune adverse events Biochemistry Cancer Cancer metastasis Case Report Case reports Cell death Clinical medicine Complications and side effects CTLA-4 protein Cytotoxicity Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 1 - chemically induced Diabetes Mellitus, Type 1 - diagnosis Diabetes Mellitus, Type 1 - pathology Diabetes therapy Diabetic ketoacidosis Endocrinopathies Female Glutamate Glutamate decarboxylase Glutamic acid Health education Humans Hyperglycemia Immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy Insulin Ipilimumab Ipilimumab - administration & dosage Ipilimumab - adverse effects Ketoacidosis Lymphocytes Lymphocytes T Male Melanoma Melanoma - drug therapy Melanoma - pathology Metastases Metastasis Middle Aged Monoclonal antibodies Nivolumab Nivolumab - administration & dosage Nivolumab - adverse effects Patient education Patients PD-1 protein PD-L1 protein Physicians Primary care Sitagliptin Skin Neoplasms - drug therapy Skin Neoplasms - pathology Targeted cancer therapy Thyroid gland Type 1 diabetes Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune adverse events. ICI-induced type 1 diabetes mellitus (T1DM) is extremely rare (
ISSN:	1472-6823 1472-6823
DOI:	10.1186/s12902-019-0467-z